Prosecution Insights
Prosecution Insights
Technology area: Biotechnology & Pharmaceuticals
2 pending office actions • 2 art units • 2 examiners • 0 of 2 (0%) have an AI response strategy ready
BASECURE THERAPEUTICS LLC has a highly focused prosecution profile with 1 pending office action in the Biotechnology & Pharmaceuticals technology area. This matter is assigned to 1 distinct examiner within a distinct art unit. The narrow scope of current activity suggests a concentrated effort on a specific patent application rather than a broad portfolio approach.
The busiest examiner, POLIAKOVA-GEORGAN, EKATERINA, is responsible for the pending office action currently on record. Because the portfolio involves a distinct examiner and a distinct art unit, the prosecution strategy is entirely dependent on the interactions within this administrative channel. This concentration allows for a deep focus on the specific technical requirements of the examiner.
The absence of other pending matters indicates that the company is currently prioritizing this particular application within the Biotechnology & Pharmaceuticals sector. Practitioners should monitor this single relationship closely, as the examiner's feedback will set the precedent for any future filings in this art unit. The singular nature of the prosecution footprint simplifies the management of deadlines and responses.
Based on the USPTO statutory response window for each pending office action. 2 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §103 only | 1 (50%) |
| Multi-statute (no §101) | 1 (50%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| VANHORN, ABIGAIL LOUISE | 1 | 46.8% | +22.4% |
| POLIAKOVA-GEORGAN, EKATERINA | 1 | 64.0% | +18.0% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 19245022 | COMPOSITIONS AND METHODS FOR INHIBITION OF EXPRESSION OF INHIBIN SUBUNIT BETA E (INHBE) GENES | POLIAKOVA-GEORGAN, EKATERINA | 76d |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 2 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 19245028 | COMPOSITIONS AND METHODS FOR INHIBITION OF EXPRESSION OF INHIBIN SUBUNIT BETA E (INHBE) GENES | VANHORN, ABIGAIL LOUISE | 28d |
| 19245022 | COMPOSITIONS AND METHODS FOR INHIBITION OF EXPRESSION OF INHIBIN SUBUNIT BETA E (INHBE) GENES | POLIAKOVA-GEORGAN, EKATERINA | 76d |
| Art Unit | Apps |
|---|---|
| 1636 | 1 |
| 1637 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 19245028 | COMPOSITIONS AND METHODS FOR INHIBITION OF EXPRESSION OF INHIBIN SUBUNIT BETA E (INHBE) GENES | VANHORN, ABIGAIL LOUISE | 1636 | §103Other | Non-Final OA | 28d | Pending | Jun 20, 2025 |
| 19245022 | COMPOSITIONS AND METHODS FOR INHIBITION OF EXPRESSION OF INHIBIN SUBUNIT BETA E (INHBE) GENES | POLIAKOVA-GEORGAN, EKATERINA | 1637 | §102§103 | Final Rejection | 76d | Pending | Jun 20, 2025 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial